Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
About the Author Michael Fulks, MD, Consulting Medical Director, is board-certified in internal and insurance medicine
Currently, the three leading options prescribed specifically for weight loss are: Semaglutide (Ozempic/Wegovy) Average weight loss: 14 to 16% of body weight FDA-approved for chronic weight management Tirzepatide (Zepbound) Average weight loss: 20 to 22% of body weight FDA-approved for chronic weight management A dual GLP-1/GIP receptor agonist that has shown superior weight loss results compared to semaglutide alone roughly 20% body weight reduction vs
Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, et al
While the test doesn't prescribe a specific injection time, it reveals whether you're genetically predisposed to rapid appetite suppression or delayed responsedata that helps you and your provider choose morning versus evening dosing strategically
